Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287929 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL17822576 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3336877 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001106 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3336886 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001104 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3010731 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL15345921 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL15345922 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL3989029 | 0.81 | HCAR2 (0.39) | HCRTR1HCRTR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190135768-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-09 | — | — | US | disclosed |
| WO-2018141821-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2018-08-09 | — | — | WO | disclosed |
| EP-3307738-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016201225-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-12-15 | — | — | WO | disclosed |
| CN-101848905-A | Process for the enantioselective preparation of pregabalin | ESTEVE LABOR DR | 2010-09-29 | — | — | CN | disclosed |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-6518305-B1 | For inhibiting neuraminidases from disease- causing microorganisms, especially, influenza neuraminidase | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| US-6310221-B1 | PREPARING A 4-FLUOROPHENOXYMETHYL-(HYDROXY)-TETRAHYDROFURAN BY REACTING 4-FLUOROPHENOL AND AN EPOXY COMPOUND; REACTING THE EPOXY-PHENYL ETHER WITH AN ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; AND REDUCING THE LACTONE | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| EP-1102759-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001028979-A2 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-1087938-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000001683-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999054290-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0427773-A1 | METHOD OF PREPARATION OF 2',3'-DIDEOXYNUCLEOSIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4987224-A | Method of preparation of 2',3'-dideoxynucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-22 | — | — | US | disclosed |
| WO-1990001492-A1 | METHOD OF PREPARATION OF 2',3'-DIDEOXYNUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1990-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135768-A1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | LANCL2 3638/4885HCRTR1 247/4885HCRTR2 194/4885 |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | LANCL2 3685/4885HCRTR1 341/4885HCRTR2 275/4885 |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | LANCL2 3657/4885HCRTR1 317/4885HCRTR2 274/4885 |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | GABRE, CYP2D6, GABRG2 | LANCL2 1467/4885HCRTR1 1977/4885HCRTR2 1411/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | LANCL2 3625/4885HCRTR1 273/4885HCRTR2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.